Resmed Inc’s recently made public that its Officer Farrell Michael J. acquired Company’s shares for reported $2.27 million on Aug 07 ’25. In the deal valued at $282.83 per share,8,009 shares were bought.
Then, Sandercock Brett sold 3,000 shares, generating $845,700 in total proceeds. Upon selling the shares at $281.90, the Chief Financial Officer now owns 83,283 shares.
Before that, Rider Michael J sold 50 shares. Resmed Inc shares valued at $14,095 were divested by the Global General Counsel at a price of $281.90 per share. As a result of the transaction, Rider Michael J now holds 8,486 shares, worth roughly $2.41 million.
RBC Capital Mkts upgraded its Resmed Inc [RMD] rating to an Outperform from a a Sector perform in a research note published recently. A number of analysts have revised their coverage, including Morgan Stanley’s analysts, who began to cover the stock in mid March with a ‘”an Overweight”‘ rating. Morgan Stanley began covering RMD with “an Overweight” recommendation on March 19, 2025. Goldman started covering the stock on January 16, 2025. It rated RMD as “a Buy”.
Price Performance Review of RMD
On Friday, Resmed Inc [NYSE:RMD] saw its stock jump 1.33% to $283.9. Over the last five days, the stock has gained 1.68%. Resmed Inc shares have risen nearly 29.74% since the year began. Nevertheless, the stocks have risen 24.14% over the past one year. While a 52-week high of $293.08 was reached on 08/04/25, a 52-week low of $199.92 was recorded on 04/07/25.
Levels Of Support And Resistance For RMD Stock
The 24-hour chart illustrates a support level at 280.76, which if violated will result in even more drops to 277.62. On the upside, there is a resistance level at 285.89. A further resistance level may holdings at 287.88.
How much short interest is there in Resmed Inc?
A steep rise in short interest was recorded in Resmed Inc stocks on 2025-07-15, dropping by -0.55 million shares to a total of 9.38 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 9.93 million shares. There was a decline of -5.89%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 10, 2025 when Piper Sandler began covering the stock and recommended ‘”a Neutral”‘ rating along with a $252 price target.
